Bacteria remain both an indispensable ally as well as a medical enemy. Humanity suffers from more than two billion bacterial infections every year while beneficial bacteria in our microbiomes support our metabolism and keep us healthy. As the effectiveness of broad-spectrum antibiotics fade to combat illness and their side effects on the beneficial microbiomes becomes clearer, it is urgently required to develop novel precision anti-bacterials.
Our client is a biotech company focused on the development of human therapeutic applications of phages and phage-derived proteins.
Currently they have three active development programs that are based on the experiences of its clinical co-founders with lastresort treatments, as well as research collaborations with highly prestigious scientists and research institutions in Germany and Belgium. Since its incorporation, the company has raised more than €6.5 million in private investments and public grants and is currently raising its Series A.
What they are looking for in you:
Welcome add-on qualifications
If this sounds of interest to you, don't delay in applying or give us a call as this is a great opportunity to really make a difference.
Kaizen Life Sciences Limited is acting as an Employment Agency in relation to this vacancy. Kaizen Life Sciences Limited is an Equal Opportunities Employer. Due to a high volume of applications we will only be able to contact successful applicants within 5 working days. We may, however, contact you regarding other potential roles of interest.